Seven pharma join Parkinson's consortium
London | 24 February 2016

Seven pharmaceutical companies have joined an initiative that is aiming to speed up the development of effective therapies for Parkinson’s.

AbbVie, AstraZeneca, Biogen, Eli Lilly, Merck Sharpe and Dohme, Pfizer and UCB have signed up to Critical Path for Parkinson’s, which was formed in October 2015 by Parkinson’s UK and the Critical Path Institute and aims to increase investment in the research and development of new Parkinson’s treatments.

“We see the consortium as a crucial part of strategies to develop new treatments that work at the earliest stage of the condition,” commented Dr Arthur Roach, director of research at Parkinson’s UK.

Diane Stephenson, executive director of the Critical Path for Parkinson’s consortium, added: “There is a strong realisation from the industry that collaboration among industry, academia, and worldwide regulatory agencies, along with the sharing of data, has the potential to create a more efficient development process.”

"This recognition is evidenced by the fast pace at which members of this new consortium have joined.”

Author: Tammy Facey

More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization